



DEPARTMENT OF HEALTH & HUMAN SERVICES

Food and Drug Administration
Rockville MD 20857

FEB 23 2011

Re: Vimpat
US Patent Nos. 5,654,301 and RE38,551
New Drug Application 22-253
Docket Nos. FDA-2009-E-0172
FDA 2009-E-0174

The Honorable David J. Kappos
Under Secretary of Commerce for Intellectual Property
Director of the United States Patent and Trademark Office
Mail Stop Hatch-Waxman PTE
P.O. Box 1450 Alexandria, VA 22313-1450

Dear Director Kappos:

This is in regard to the patent term extension applications for U.S. Patent Nos. 5,654,301 and RE38,551 filed by Research Corporation Technologies, Inc. under 35 U.S.C. § 156. The patents claim Vimpat (laçosamide), new drug application (NDA) 22-253.

In the April 23, 2010, issue of the Federal Register (75 Fed. Reg. 21298), the Food and Drug Administration published its determination of this product's regulatory review period, as required under 35 U.S.C. § 156(d)(2)(A). The notice provided that on or before October 20, 2010, 180 days after the publication of the determination, any interested person could file a petition with FDA under 35 U.S.C. § 156(d)(2)(B)(i) for a determination of whether the patent term extension applicant acted with due diligence during the regulatory review period.

The 180-day period for filing a due diligence petition pursuant to this notice has expired and FDA has received no such petition. Therefore, FDA considers the regulatory review period determination to be final.

Please let me know if we can provide further assistance.

Sincerely yours,

Jane A. Axelrad
Associate Director for Policy
Center for Drug Evaluation and Research

cc: Kevin G. Shaw
Hogan & Hartson, LLP
555 Thirteenth Street, NW
Washington, DC 20004